ESG
  • ESG Home
  • ESG at PEC
    • Letter from the management team
    • ESG Strategies & Goals
    • ESG Governance & Risk Management
    • ESG Materiality Metrics & Stakeholders Engagement
    • ESG Performance Highlights
  • Our Focuses
    • Innovation
    • Business ethics , integrity and compliance
    • Product quality and patient safety
    • Human capital management
    • Environmental impacts
    • Access to healthcare and medicine pricing
  • News
  • Downloads
    • ESG Reports
    • Annual Reports
    • SASB
  • Interactions
    • Questionnaire
    • Video
  • Contact Us
    • 繁體中文
    • English
  • ESG Home
  • ESG at PEC
    • Letter from the management team
    • ESG Strategies & Goals
    • ESG Governance & Risk Management
    • ESG Materiality Metrics & Stakeholders Engagement
    • ESG Performance Highlights
  • Our Focuses
    • Innovation
    • Business ethics , integrity and compliance
    • Product quality and patient safety
    • Human capital management
    • Environmental impacts
    • Access to healthcare and medicine pricing
  • News
  • Downloads
    • ESG Reports
    • Annual Reports
    • SASB
  • Interactions
    • Questionnaire
    • Video
  • Contact Us

News

  • All
  • Media
  • PEC Latest Newsletter

2022 / 08 / 02

The Execution Center for Corporate Sustainability hold the first ESG education and training in 2022

2022 / 07 / 25

PharmaEssentia Climate Governance : GHG management and internal verifier education & training

2022 / 06 / 30

PharmaEssentia(6446) earns top ESG scores and announces to release 2021 Sustainability Reports both in English and Chinese simultaneously today

2022 / 06 / 22

PHARMAESSENTIA HONORED AT THE NATIONAL ORGANIZATION OF RARE DISORDERS (NORD®) 2022 RARE IMPACT AWARDS FOR THE INTRODUCTION OF BESREMI® (ROPEGINTERFERON ALFA-2B-NJFT) FOR POLYCYTHEMIA VERA

2022 / 05 / 24

PharmaEssentia Compliance training: IRPMA COP Updates and Remind

2022 / 04 / 27

Pharmaessentia Japan Files Marketing Authorization Application for Ropeginterferon Alfa-2b for the Treatment of Polycythemia Vera

/ 7
ESG at PEC
  • Letter from the management team
  • ESG Strategies & Goals
  • ESG Governance & Risk Management
  • ESG Materiality Metrics & Stakeholders Engagement
  • ESG Performance Highlights
Our Focuses
  • Innovation
  • Business ethics , integrity and compliance
  • Product quality and patient safety
  • Human capital management
  • Environmental impacts
  • Access to healthcare and medicine pricing
  • News
  • Downloads
  • Interactions
  • Contact Us
  • Privacy policy

Copyright © 2022 PharmaEssentia Corporation.
WEB DESIGN

We use cookies to enhance your browsing experience and for web traffic statistics purposes. By using this website, you agree to our cookies technical support. Learn more, please refer to our PRIVACY AND COOKIES PLOICY. Privacy policy